GlassScriptPhysician profile
Charisse J Ward
NPI 1528243300
$8,892.52
in general payments reported to CMS, 2019-2025
24 companies · $85.55 in 2025
The $85.55 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,439 · 2020: $173 · 2021: $130 · 2022: $2,929 · 2023: $44.62 · 2024: $91.61 · 2025: $85.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $221.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $4,638.49 | 2019 | |
| Medtronic, INC. | $2,790.30 | 2022 | |
| Boston Scientific Corporation | $448.87 | 2019-2021 | |
| Medtronic Vascular, INC. | $141.24 | 2019 | |
| Veryan Medical Incorporated | $138.72 | 2022 | |
| Edwards Lifesciences Corporation | $132.56 | 2019 | |
| Abbott Laboratories | $91.86 | 2019-2025 | Cardiomems |
| Philips North America LLC | $88.95 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.75 | 2020-2024 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $59.93 | 2019-2020 | |
| Amgen INC. | $43.17 | 2019 | |
| Scpharmaceuticals INC. | $25.97 | 2024 | |
| Amarin Pharma, INC. | $25.94 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $23.96 | 2019 | |
| Shockwave Medical, INC | $22.15 | 2023 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave M5+ |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $20.30 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $18.97 | 2025 | |
| Esperion Therapeutics, INC. | $18.53 | 2020 | |
| Novartis Pharmaceuticals Corporation | $18.25 | 2025 | |
| Gilead Sciences, INC. | $17.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.43 | 2020 | |
| Silk Road Medical, INC. | $16.33 | 2021 | |
| Novo Nordisk INC | $15.03 | 2024 | Rybelsus, Ozempic |
| Smith+Nephew, INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charisse Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.